Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia

NCT04159103 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04159103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04159103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 15, 2021
Completion date
August 31, 2027
Enrollment
77 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

propionic acidemia